TIDMHIK 
 
RNS Number : 4888S 
Hikma Pharmaceuticals Plc 
19 May 2009 
 

 
 
Hikma Pharmaceuticals PLC - LTIP Awards 
 
 
LONDON, 19 May 2009: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: 
HIK) announces that the Remuneration Committee has made the following nil-cost 
awards under the Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan (the 
"LTIP") to Persons Discharging Managerial Responsibility ("PDMRs") of the 
Company. 
 
 
Awards under the LTIP were made on 19 May 2009 at a price of 421.25 pence per 
ordinary share as follows:- 
 
 
+---------------------------------------+---------------------------------------+ 
| Name of Director                      | Number of LTIP Shares                 | 
| Said Darwazah                         | 125,000                               | 
+---------------------------------------+---------------------------------------+ 
| Mazen Darwazah                        | 75,000                                | 
+---------------------------------------+---------------------------------------+ 
 
 
The shares subject to the LTIP awards will only be released to the participants 
in three years time, subject to their continued employment and the satisfaction 
of the comparative Total Shareholder Return ("TSR") performance target. 
Participants will only receive the full benefit of their share incentives if TSR 
performance against the Comparator Group is at least at the upper quartile. 
 
 
- ENDS - 
 
 
Enquiries: 
 
 
Hikma Pharmaceuticals PLC 
Henry Knowles     +44 20 7399 2760 
Company Secretary 
 
 
Susan Ringdal +44 20 7399 2760 
Investor Relations Director 
 
 
About Hikma 
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on 
developing, manufacturing and marketing a broad range of both branded and 
non-branded generic and in-licensed pharmaceutical products.  Hikma's operations 
are conducted through three businesses: "Branded", "Injectables" and "Generics". 
 Hikma's operations are based principally in the Middle East and North Africa 
("MENA") region, where it is a market leader and sells across 17 countries, the 
United States and Europe.  In 2008, the Group achieved revenues of $580.7 
million (2007 $449 million) and profit attributable to shareholders was $57.1 
million (2007 $63 million).  For news and other information, please visit 
www.hikma.com. 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 RDSGCGDUBSBGGCC
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Hikma Pharmaceuticals Charts.
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Hikma Pharmaceuticals Charts.